NetworkNewsBreaks – Endonovo Therapeutics Inc. (
Post# of 416
(Total Views: 1000)
Posted On: 08/30/2019 9:10:34 PM
NetworkNewsBreaks – Endonovo Therapeutics Inc. (ENDV) Appoints New Member to Scientific Advisory Board
Endonovo Therapeutics (OTCQB: ENDV), a commercial-stage developer of noninvasive Electroceutical® therapeutic devices, this morning announced the appointment of orthopedic surgeon Dr. Geoffrey Abrams to its scientific advisory board. Dr. Abrams is an assistant professor of orthopedic surgery at the Stanford University School of Medicine as well as the director of sports medicine for Stanford’s varsity athletes. “We are thrilled to announce that Dr. Abrams is joining the Endonovo family by serving on the scientific advisory board. His participation will be instrumental as we continue to introduce the SofPulse® technology to post-surgical care to fight the opioid epidemic,” Endonovo CEO Alan Collier stated in the news release. “We look forward to working with Dr. Abrams’ team in designing a clinical trial of SofPulse® for post-operative pain and evaluating functional outcomes in shoulder surgery. We believe such a study will further validate the SofPulse® technology application across the orthopedic indications. This is a fantastic relationship and I could not be more pleased about Dr. Abrams’ enthusiasm and interest in helping his own patients as well as studying the technology for other indications as we plan expansion of the label in the future.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Endonovo Therapeutics (OTCQB: ENDV), a commercial-stage developer of noninvasive Electroceutical® therapeutic devices, this morning announced the appointment of orthopedic surgeon Dr. Geoffrey Abrams to its scientific advisory board. Dr. Abrams is an assistant professor of orthopedic surgery at the Stanford University School of Medicine as well as the director of sports medicine for Stanford’s varsity athletes. “We are thrilled to announce that Dr. Abrams is joining the Endonovo family by serving on the scientific advisory board. His participation will be instrumental as we continue to introduce the SofPulse® technology to post-surgical care to fight the opioid epidemic,” Endonovo CEO Alan Collier stated in the news release. “We look forward to working with Dr. Abrams’ team in designing a clinical trial of SofPulse® for post-operative pain and evaluating functional outcomes in shoulder surgery. We believe such a study will further validate the SofPulse® technology application across the orthopedic indications. This is a fantastic relationship and I could not be more pleased about Dr. Abrams’ enthusiasm and interest in helping his own patients as well as studying the technology for other indications as we plan expansion of the label in the future.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)